ReviewFrontiers in allergy2023
The role of the respiratory microbiome in asthma.
Review in Frontiers in allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Asthma Dysbiosis Index: A Universal Airway Microbiome Signature From Multi-Cohort Analysis.Pediatric pulmonology · 2026Article
- The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.Microorganisms · 2026Review
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Review
- Functional and Resistome Profiling of Paediatric Airway Microbiota in Asthma Using Shotgun Metagenomics.Biomedicines · 2026Article
- From disease to syndrome pattern: a study on the differentiation of traditional Chinese medicine syndrome patterns in asthma using multi-omics characterization.Frontiers in immunology · 2026Article
- Microbiota-Driven Immune Dysregulation Along the Gut-Lung-Vascular Axis in Asthma and Atherosclerosis.Biomedicines · 2025Review
- The Role of the Oral Microbiome and Dental Caries in Respiratory Health: A Systematic Review.Journal of clinical medicine · 2025Review
- New Asthma Diagnosis Codes or Short-Acting βMycoses · 2025Article
- Prevalence and Clinical Characteristics of Severe Asthma With Fungal Sensitization in Korea.Allergy, asthma & immunology research · 2025Article
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
- Diversity and Meta-Analysis of Microbial Differential Abundance in Nasal Metatranscriptomic Profiles of Asthma.Journal of respiratory biology and translational medicine · 2024Article
- A clinician's guide to effects of obesity on childhood asthma and into adulthood.Expert review of respiratory medicine · 2024Review
- The Microbiota in Children and Adolescents with Asthma.Children (Basel, Switzerland) · 2024Review
- Does Eosinophil Heterogeneity Translate into Functional Diversity? A Review of the Evolving Paradigm of Eosinophil Heterogeneity in Asthma.Biomedicines · 2024Review
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- A Comprehensive Look at the Development of Asthma in Children.Children (Basel, Switzerland) · 2024Review
- The Lung Microbiome.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- Omics approaches in asthma research: Challenges and opportunities.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Adjuvant-independent airway sensitization and infection mouse models leading to allergic asthma.Frontiers in allergy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common airways disease and the human microbiome plays an increasingly recognised role in asthma pathogenesis. Furthermore, the respiratory microbiome varies with asthma phenotype, endotype and disease severity. Consequently, asthma therapies have a direct effect on the respiratory microbiome. Newer biological therapies have led to a significant paradigm shift in how we treat refractory Type 2 high asthma. While airway inflammation is the generally accepted mechanism of action of all asthma therapies, including both inhaled and systemic therapies, there is evidence to suggest that they may also alter the microbiome to create a more functionally balanced airway microenvironment while also influencing airway inflammation directly. This downregulated inflammatory cascade seen biochemically, and reflected in improved clinical outcomes, supports the hypothesis that biological therapies may in fact affect the microbiome-host immune system dynamic and thus represent a therapeutic target for exacerbations and disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.